Microsoft shares jump after fourth-quarter earnings beat on AI-fueled cloud growth
Investing.com - H.C. Wainwright has reiterated its Buy rating and $8.00 price target on Zynex Inc. (NASDAQ:ZYXI) following the company’s announcement of a new CEO appointment. The medical technology company, currently trading at $2.58, has seen its shares decline over 71% in the past year, according to InvestingPro data.
Zynex announced Monday that Steven Dyson will join as Chief Executive Officer effective August 18, 2025. Dyson brings over 25 years of experience in the medical technology sector, primarily through his leadership position at global private equity firm Apax (HN:IBC). The appointment comes as the company, which InvestingPro analysis shows is currently undervalued, maintains a strong liquidity position with a current ratio of 3.46.
According to H.C. Wainwright, Dyson is expected to help Zynex refocus its business strategy toward a more optimized payer mix and work to return the company to a strong growth trajectory.
The incoming CEO holds a B.A. from Oxford University and a Ph.D. from Cambridge University, bringing significant academic credentials to the leadership position.
Thomas Sandgaard, Zynex’s Founder and current Chairman of the Board, will remain actively involved with the company as Chairman and Chair of the Board’s Technology Committee following the leadership transition.
In other recent news, Zynex Inc. reported disappointing financial results for the first quarter of 2025, with earnings per share at -$0.33, missing the forecasted $0.06, and revenue at $26.58 million, significantly below the anticipated $53.47 million. The company is also undergoing a workforce reduction affecting 86 corporate roles, which is expected to save approximately $5 million annually. Zynex has secured a UK patent for a noninvasive sepsis monitoring device, aiming to contribute to early detection and potentially reduce mortality rates associated with sepsis. Additionally, Zynex has appointed Steven Dyson as the new CEO, effective August 18, 2025, as part of a strategic shift in leadership. The company is facing challenges with a temporary suspension of payments by Tricare, which they have appealed but have not yet received a response. Zynex is also focusing on launching the NICO Pulse Oximeter, anticipated to generate revenue in 2026. Analysts from firms like RBC and H.C. Wainwright have raised concerns regarding the ongoing issues with Tricare and the company’s future revenue streams. The company remains optimistic about its long-term growth strategy, despite the current financial and operational challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.